Guidelines for clinical evaluation of anti‐cancer drugs-Reference-Cited by-同舟云学术

Guidelines for clinical evaluation of anti‐cancer drugs

Published:2021-06-08 Issue:7 Volume:112 Page:2563-2577
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Minami Hironobu¹²^ORCID,Kiyota Naomi¹²^ORCID,Kimbara Shiro¹,Ando Yuichi³^ORCID,Shimokata Tomoya³,Ohtsu Atsushi⁴,Fuse Nozomu⁵,Kuboki Yasutoshi⁶,Shimizu Toshio⁷^ORCID,Yamamoto Noboru⁷^ORCID,Nishio Kazuto⁸^ORCID,Kawakami Yutaka⁹,Nihira Shin‐ichi¹⁰,Sase Kazuhiro¹¹,Nonaka Takahiro¹²^ORCID,Takahashi Hideaki¹³,Komori Yukiko¹⁴,Kiyohara Koshin¹³

Affiliation:

1. Division of Medical Oncology and Hematology Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan

2. Cancer Center Kobe University Hospital Kobe Japan

3. Department of Clinical Oncology and Chemotherapy Nagoya University Hospital Nagoya Japan

4. National Cancer Center Hospital East Kashiwa Japan

5. Clinical Research Support Office National Cancer Center Hospital East Kashiwa Japan

6. Department of Experimental Therapeutics National Cancer Center Hospital East Kashiwa Japan

7. Department of Experimental Therapeutics National Cancer Center Hospital Tokyo Japan

8. Department of Genome Biology Kindai University Faculty of Medicine Osaka Japan

9. Department of Immunology School of Medicine International University of Health and Welfare Chiba Japan

10. Tokyo Biochemical Research Foundation‐Comprehensive Academy for Advanced Oncology Tokyo Japan

11. Clinical Pharmacology & Regulatory Science Graduate School of Medicine Juntendo University Tokyo Japan

12. Division of Epidemiology Office of Medical Informatics and Epidemiology Pharmaceuticals and Medical Devices Agency Tokyo Japan

13. Office of New Drug V Pharmaceuticals and Medical Devices Agency Tokyo Japan

14. Office of New Drug IV Pharmaceuticals and Medical Devices Agency Tokyo Japan

Funder

Japan Agency for Medical Research and Development

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14967

Reference76 articles.

1. Guidelines for clinical evaluation of anti‐cancer drugs. Ministry of Health and Welfare;2021.https://www.mhlw.go.jp/hourei/doc/tsuchi/T210401I0060.pdf. Accessed April 2021.

2. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

3. Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials

4. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

5. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent status of Phase I clinical trials for brain tumors: a regulatory science study of exploratory efficacy endpoints;2024-01-25

2. Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies;Biomedicines;2024-01-16

3. Oncology drug lag in Japan: has it improved over the last decade?;International Journal of Clinical Oncology;2023-08-10

4. Comprehensive Analysis of Cuproptosis Genes and Identification of Cuproptosis Subtypes in Breast Cancer;Combinatorial Chemistry & High Throughput Screening;2023-07

5. Oncology drug lag in Japan – Has it improved over the last decade?;2023-05-04